No Data
No Data
VYNE Therapeutics Sees Strong Shareholder Support for Growth
VYNE Therapeutics Initiated With a Buy at BTIG on I&I Potential
Vyne Therapeutics Initiated at Buy by BTIG
Vyne Therapeutics Price Target Announced at $8.00/Share by BTIG
VYNE Therapeutics Analyst Ratings
TD Cowen Maintains VYNE Therapeutics(VYNE.US) With Buy Rating, Maintains Target Price $5